Yuyu Pharma, Inc. (000225.KS)

Yuyu Pharma, Inc. (000225.KS) — VMCI valuation read

Headline read on 000225.KS: VMCI of 64/100 versus a broad-market sample median of 50. The 14-point above-median position is what makes Yuyu Pharma, Inc. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 000225.KS: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 000225.KS: value (000225.KS trades at 19.0x earnings, 6% above the sector median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the sector median (10.0%)), and risk (net debt to EBITDA of 0.1x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the sector 12.0x baseline.

000225.KS rose 2.1% over the trailing 7 days, with a -17.8% read on a 30-day basis.